> lacking the pressure that would lead to focused/cooperative effort and lots of resources pouring in
Until literally a few months ago, hacking at the level of the protein abstraction was relegated to academics. Then Chimeric Antigen Receptors cured children of cancers, and were approved by the FDA. And so in August, Kite got bought by Gilead for $12B. Then in November Gilead bought another class of multi-domain protein biotherapeutics called SynNotch for $0.5B from an 18 month old startup. And Juno got purchased yesterday for $9B again for their work on CARs - multi-domain protein biotherapeutics.
We'd like to think that such cooperative effort and resources are just starting to pour in. But up until very recently, it was not obvious what the commercial value was when working at such an abstraction layer.
That's interesting to know, thanks. Regarding the 'cooperative' aspect, though—acquisitions might be falling a bit short of the ideal imo ;) But maybe it will be enough.
Until literally a few months ago, hacking at the level of the protein abstraction was relegated to academics. Then Chimeric Antigen Receptors cured children of cancers, and were approved by the FDA. And so in August, Kite got bought by Gilead for $12B. Then in November Gilead bought another class of multi-domain protein biotherapeutics called SynNotch for $0.5B from an 18 month old startup. And Juno got purchased yesterday for $9B again for their work on CARs - multi-domain protein biotherapeutics.
We'd like to think that such cooperative effort and resources are just starting to pour in. But up until very recently, it was not obvious what the commercial value was when working at such an abstraction layer.